Company intelligence / Profile preview

SiSaf Ltd

Guildford, Surrey, United Kingdomsisaf.com ↗

Ownership: Private
Development stage: Preclinical

Overview

SiSaf is developing RNA therapeutics using its proprietary Bio-Courier technology. Its lead program for Osteopetrosis has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.

Therapeutic areas: OphthalmologyRare Diseases
Modalities: RNA therapeuticssiRNAnucleic acid-based medicines
Industry: Biotech

Drug pipeline

9 assets

SIS-401-PACA

Preclinical

8 more assets in the full pipeline.

Request access →

Partnerships

University of L’Aquila, ItalyAvellino Labs USA

Beyond the preview

Go deeper on SiSaf Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SiSaf Ltd.

Explore the full profile